Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | CNR2 | P34972 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL678573 | 0.72 | LMNA (0.42) | MEN1CYP3A4CYP2C9CYP2C19KMT2A | |
| SCHEMBL28461943 | 0.72 | MEN1 (0.35) | MEN1CYP3A4CYP2C9CYP2C19KMT2A | |
| SCHEMBL11996521 | 0.70 | RIPK1 (0.39) | MEN1CYP3A4CYP2C9CYP2C19KMT2A | |
| SCHEMBL5417010 | 0.70 | LMNA (0.36) | MEN1CYP3A4CYP2C9CYP2C19KMT2A | |
| SCHEMBL17333379 | 0.68 | MEN1 (0.33) | MEN1CYP3A4CYP2C9CYP2C19KMT2A | |
| SCHEMBL12245562 | 0.68 | MEN1 (0.33) | MEN1CYP3A4CYP2C9CYP2C19KMT2A | |
| SCHEMBL22957879 | 0.67 | MEN1 (0.31) | MEN1CYP3A4CYP2C9CYP2C19KMT2A | |
| SCHEMBL14544847 | 0.67 | CHRM2 (0.40) | MEN1CYP3A4CYP2C9CYP2C19KMT2A | |
| SCHEMBL13678599 | 0.67 | MEN1 (0.32) | MEN1CYP3A4CYP2C9CYP2C19KMT2A | |
| SCHEMBL13994290 | 0.65 | MEN1 (0.31) | MEN1CYP3A4CYP2C9CYP2C19KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180125848-A1 | PREPARATION AND METHODS OF USE FOR ORTHO-ARYL 5-MEMBERED HETEROARYL-CARBOXAMIDE CONTAINING MULTI-TARGETED KINASE INHIBITORS | VIBLIOME THERAPEUTICS, LLC | 2018-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180125848-A1 | PREPARATION AND METHODS OF USE FOR ORTHO-ARYL 5-MEMBERED HETEROARYL-CARBOXAMIDE CONTAINING MULTI-TARGETED KINASE INHIBITORS | ABL1, ERBB2, MAP3K2 | MEN1 2114/4885CYP3A4 2553/4885CYP2C9 1674/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.